Naa12 compensates for Naa10 in mice in the amino-terminal acetylation pathway
- Ewha Womans University, Republic of Korea
- Korea Research Institute of Bioscience and Biotechnology, Republic of Korea
- Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, United States
- Perelman School of Medicine, University of Pennsylvania, United States
- University of Bergen, Norway
- Department of Molecular Biology, New York State Institute for Basic Research in Developmental Disabilities, United States
- New York State Institute for Basic Research in Developmental Disabilities, United States
- Washington University School of Medicine, United States
- Korea Institute of Science and Technology, Republic of Korea
- Indiana University School of Medicine, United States
- Pohang University of Science and Technology, Republic of Korea
- George A Jervis Clinic, New York State Institute for Basic Research in Developmental Disabilities, United States
Abstract
Amino-terminal acetylation is catalyzed by a set of N-terminal acetyltransferases (NATs). The NatA complex (including X-linked Naa10 and Naa15) is the major acetyltransferase, with 40-50% of all mammalian proteins being potential substrates. However, the overall role of amino-terminal acetylation on a whole-organism level is poorly understood, particularly in mammals. Male mice lacking Naa10 show no globally apparent in vivo amino-terminal acetylation impairment and do not exhibit complete embryonic lethality. Rather Naa10 nulls display increased neonatal lethality, and the majority of surviving undersized mutants exhibit a combination of hydrocephaly, cardiac defects, homeotic anterior transformation, piebaldism and urogenital anomalies. Naa12 is a previously unannotated Naa10-like paralogue with NAT activity that genetically compensates for Naa10. Mice deficient for Naa12 have no apparent phenotype, whereas mice deficient for Naa10 and Naa12 display embryonic lethality. The discovery of Naa12 adds to the currently known machinery involved in amino-terminal acetylation in mice.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.Mass spectrometry data were uploaded to PRIDE under Project Name: Naa10 mutant mouse N-terminome LC-MS, Project accession: PXD026410.
Article and author information
Author details
Funding
National Research Foundation of Korea (2020R1A3B2079811)
- Gootaeg Oh
Norwegian Cancer Society (PR-2009-0222)
- Thomas Arnesen
National Research Foundation of Korea (2017RIDIAB03032286)
- Mi-Ni Lee
National Research Foundation of Korea (2020RICIC1007686)
- Mi-Ni Lee
National Institute of General Medical Sciences (R35GM133408)
- Gholson J Lyon
National Institute of General Medical Sciences (R35GM118090)
- Ronen Marmorstein
Research Council of Norway (Project 249843)
- Thomas Arnesen
National Institutes of Health (Project 249843)
- Simon J Conway
Norwegian Health Authorities of Western Norway (912176)
- Thomas Arnesen
Norwegian Health Authorities of Western Norway (F-12540-D11382)
- Thomas Arnesen
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Hening Lin, Cornell University, United States
Ethics
Animal experimentation: All experiments were performed in accordance with guidelines of International Animal Care and Use Committee (IACUC) of Ewha Womans University (protocol #18 012)012), Cold Spring Harbor L aboratory (CSHL) protocol # 579961 18 , and Institute for Basic Research in Developmental Disabilities (IBR) (protocol #456).
Version history
- Preprint posted: December 20, 2020 (view preprint)
- Received: December 20, 2020
- Accepted: August 5, 2021
- Accepted Manuscript published: August 6, 2021 (version 1)
- Accepted Manuscript updated: August 11, 2021 (version 2)
- Version of Record published: August 19, 2021 (version 3)
Copyright
© 2021, Kweon et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,265
- views
-
- 170
- downloads
-
- 8
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Naa12 compensates for Naa10 in mice in the amino-terminal acetylation pathway
eLife 10:e65952.
https://doi.org/10.7554/eLife.65952
Further reading
-
- Developmental Biology
- Medicine
From a forward mutagenetic screen to discover mutations associated with obesity, we identified mutations in the Spag7 gene linked to metabolic dysfunction in mice. Here, we show that SPAG7 KO mice are born smaller and develop obesity and glucose intolerance in adulthood. This obesity does not stem from hyperphagia, but a decrease in energy expenditure. The KO animals also display reduced exercise tolerance and muscle function due to impaired mitochondrial function. Furthermore, SPAG7-deficiency in developing embryos leads to intrauterine growth restriction, brought on by placental insufficiency, likely due to abnormal development of the placental junctional zone. This insufficiency leads to loss of SPAG7-deficient fetuses in utero and reduced birth weights of those that survive. We hypothesize that a ‘thrifty phenotype’ is ingrained in SPAG7 KO animals during development that leads to adult obesity. Collectively, these results indicate that SPAG7 is essential for embryonic development and energy homeostasis later in life.
-
- Developmental Biology
- Stem Cells and Regenerative Medicine
Amniogenesis, a process critical for continuation of healthy pregnancy, is triggered in a collection of pluripotent epiblast cells as the human embryo implants. Previous studies have established that bone morphogenetic protein (BMP) signaling is a major driver of this lineage specifying process, but the downstream BMP-dependent transcriptional networks that lead to successful amniogenesis remain to be identified. This is, in part, due to the current lack of a robust and reproducible model system that enables mechanistic investigations exclusively into amniogenesis. Here, we developed an improved model of early amnion specification, using a human pluripotent stem cell-based platform in which the activation of BMP signaling is controlled and synchronous. Uniform amniogenesis is seen within 48 hr after BMP activation, and the resulting cells share transcriptomic characteristics with amnion cells of a gastrulating human embryo. Using detailed time-course transcriptomic analyses, we established a previously uncharacterized BMP-dependent amniotic transcriptional cascade, and identified markers that represent five distinct stages of amnion fate specification; the expression of selected markers was validated in early post-implantation macaque embryos. Moreover, a cohort of factors that could potentially control specific stages of amniogenesis was identified, including the transcription factor TFAP2A. Functionally, we determined that, once amniogenesis is triggered by the BMP pathway, TFAP2A controls the progression of amniogenesis. This work presents a temporally resolved transcriptomic resource for several previously uncharacterized amniogenesis states and demonstrates a critical intermediate role for TFAP2A during amnion fate specification.
